(Total Views: 654)
Posted On: 08/31/2020 2:40:01 PM
Post# of 153986
Agreed C Diddy , very much agreed
That's what this says YALE said, HIV was covered we are doing a different area, inflammatory diseases:
" While many companies have focused on CCR5 antagonists for HIV treatments, CCR5 antagonists may also address a wide range of inflammatory diseases that affect a significant number of patients. "
"Field of Application:
Inflammatory diseases including but not limited to asthma, COPD, interstitial lung disease, chronic obstructive lung disease, chronic bronchitis, eosinophilic bronchitis, eosinophilic pneumonia, pneumonia, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, idiopathic pulmonary fibrosis, scleroderma, and emphysema."
https://ocr.yale.edu/available-technologies/c...flammation
That's what this says YALE said, HIV was covered we are doing a different area, inflammatory diseases:
" While many companies have focused on CCR5 antagonists for HIV treatments, CCR5 antagonists may also address a wide range of inflammatory diseases that affect a significant number of patients. "
"Field of Application:
Inflammatory diseases including but not limited to asthma, COPD, interstitial lung disease, chronic obstructive lung disease, chronic bronchitis, eosinophilic bronchitis, eosinophilic pneumonia, pneumonia, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, idiopathic pulmonary fibrosis, scleroderma, and emphysema."
https://ocr.yale.edu/available-technologies/c...flammation
(2)
(3)
